EP3313868A1 - Composition immunogène - Google Patents

Composition immunogène

Info

Publication number
EP3313868A1
EP3313868A1 EP16733421.8A EP16733421A EP3313868A1 EP 3313868 A1 EP3313868 A1 EP 3313868A1 EP 16733421 A EP16733421 A EP 16733421A EP 3313868 A1 EP3313868 A1 EP 3313868A1
Authority
EP
European Patent Office
Prior art keywords
seq
gliadin
polypeptide
peptides
terminal domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16733421.8A
Other languages
German (de)
English (en)
Inventor
Sandra DENERY
Hamza MAMERI
Jean-Charles GAUDIN
Jacques SNEGAROFF
Chantal BROSSARD
Colette Larre
Olivier TRANQUET
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de Recherche pour lAgriculture lAlimentation et lEnvironnement
Original Assignee
Institut National de la Recherche Agronomique INRA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Recherche Agronomique INRA filed Critical Institut National de la Recherche Agronomique INRA
Priority to EP21163171.8A priority Critical patent/EP3868777A1/fr
Priority claimed from PCT/EP2016/064697 external-priority patent/WO2016207367A1/fr
Publication of EP3313868A1 publication Critical patent/EP3313868A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • the present invention relates to an immunogenic polypeptide for use as a medicament.
  • said immunogenic polypeptide comprises the N -terminal domain of an a-gliadin or a ⁇ -gliadin, or a fragment of the N-terminal domain of an a-gliadin or a ⁇ -gliadin, and is for use as an agent for desensitization of an individual with diagnosed IgE-dependent gluten allergy.
  • IgE immunoglobulin E
  • a substance called histamine or other substances such as leukotrienes and prostaglandins are released from mast cells and basophils subsequently causing allergic responses such as (i) a respiratory response, such as runny nose or nasal congestion, sneezing, asthma, coughing, wheezing, breathing difficulties; (ii) a skin response, such as swelling of the lips, mouth, tongue, face and/or throat (angio -oedema), hives, rashes or redness, pruritus, eczema; (iii) a gastrointestinal response, such as abdominal cramps, diarrhoea, nausea, vomiting, colic, bloating; and/or (iv) a systemic response, namely an anaphylactic shock (severe generalised shock).
  • a respiratory response such as runny nose or nasal congestion, sneezing, asthma, coughing, wheezing, breathing difficulties
  • a skin response such as swelling of the lips, mouth, tongue,
  • gluten allergies are among the tenth most prevalent food allergies, after cow's milk or peanut allergies to name a few.
  • Gluten consists in an admixture of proteins belonging to the prolamin superfamily, such as gliadins and glutenins.
  • the prolamin superfamily comprises the largest number of allergenic plant proteins. It includes proteins such as the sulphur-rich prolamins, the seed storage 2S albumins, the nonspecific lipid transfer proteins (LTP) and the cereal a-amylase/ trypsin inhibitors (ATI) that are involved in food or respiratory allergies.
  • Prolamin superfamily members are grouped on the basis on a conserved skeleton of 8 cysteine residues that are connected by intramolecular disulphide bonds. In LTPs, 2S albumins and ATIs, these disulphide bonds contribute significantly to the stabilization of a compact, a-helix-rich 3D structure that is resistant to thermal and enzymatic denaturation and plays an essential role in the allergenic potential of these proteins.
  • the sulphur-rich prolamins, a-gliadins, ⁇ -gliadins and low molecular weight (LMW) glutenin subunits differ from the other members of the prolamin superfamily by their organization into two structural domains: the C -terminal (Ct-) domain, which include the cysteine skeleton, and the N-terminal (Nt-) domain, which contains repeating motifs that are rich in glutamine and proline residues.
  • Ct- C -terminal
  • Nt- N-terminal domain
  • WO 2003/104273 discloses a method of desensitisation as a treatment of the celiac disease, based on fragments of N-terminal domain of a-gliadin.
  • Huibregtse et al. J. Immunol. 2009, 183, 2390-2396 discloses the identification of an epitope borne by the C-terminal domain of a-gliadin, which may be involved in tolerance.
  • the physiological mechanisms involved in the celiac disease and the wheat allergies are distinct.
  • the celiac disease is an inflammatory disease, wherein the T cells are activated upon recognition of the epitopes borne by the gliadine proteins, through the MHC complex.
  • the celiac disease encompasses an immune response that is IgE- independent.
  • the wheat allergy is mediated by blood circulating IgEs. Therefore, the epitopes involved in celiac diseases are necessarily distinct from the epitopes involved in wheat allergy, although overlapping may be observed.
  • a minor role of a-gliadin was also reported in bakers with occupational asthma (Bittner et al; J. Allergy Clin. Immunol. 2008, 121, 744-749; Sander et al. Allergy 2011, 66, 1208-1215). IgE-binding epitopes of gliadins were primarily found in the repetitive domains of these proteins (Denery-Papini et al; Clin. Exp. Allergy 2011, 41, 1478-1492, Battais et al.; Allergy 2005, 60, 815-821 ; Matsuo et al; FEBS J. 2005, 272, 4431-4438; Tanabe; J. Nutr. Sci. Vitaminol.
  • gliadins present a very large intra- and inter-cultivar polymorphism; thus, each gliadin sub-group contains many homologous proteins (Dupont et al.; Proteome Sci. 2011, 9, 10; Metakovsky et al; J. Genet. Breed 1991, 45, 325-344). Purifying individual natural gliadins is thus very difficult. To overcome these problems, recombinant proteins are an alternative way. Some recombinant prolamin allergens have already been produced and characterized (Bittner et al; J. Allergy Clin. Immunol. 2008, 121, 744-749; Sander et al.
  • Well-defined protein fragments can also be produced by heterologous expression, and such recombinant fragments have been valuable for studying the antigenicity of LMW glutenin subunits and their two domains (Mameri et al; J. of Agric. Food Chem., 2012, 60, 7538-7547) as well as fragments of HMW glutenins (Baar et al.; Allergy, 2014, 69, 1316-1323).
  • the invention relates to an immunogenic composition
  • an immunogenic composition comprising:
  • polypeptide or a mixture of polypeptides comprising the N-terminal domain of an a-gliadin or a ⁇ -gliadin, or a fragment of the N-terminal domain of an a-gliadin or a ⁇ -gliadin;
  • the invention also relates to an immunogenic composition or polypeptide according to the invention, for use as a medicament.
  • the invention also relates to an immunogenic composition or polypeptide according to the invention, for use as an antigenic compound.
  • the invention also relates to an immunogenic composition or polypeptide according to the invention, for use as an agent for desensitization of individual with an IgE-dependent gluten allergy.
  • the invention also relates to a method for desensitization of an individual with an IgE-dependent gluten allergy comprising a step of administering to said individual an immunogenic composition comprising a polypeptide comprising a N- terminal domain of an a-gliadin or a ⁇ -gliadin, or a fragment thereof, optionally linked to a carrier molecule.
  • Figure 1 Illustration of a SDS-PAGE analysis of the proteins under reducing conditions coloured with Coomassie Brilliant Blue R250.
  • "rAG” SEQ ID No. 3
  • “rGG” SEQ ID No. 4
  • rNt-AG SEQ ID No. 5
  • “rNt-GG” SEQ ID No. 6
  • rAG-Ct SEQ ID No. 7
  • rGG-Ct SEQ ID No.
  • nAG SEQ ID No. 1
  • nGG SEQ ID No. 2
  • Figure 2 Plots displaying the Synchrotron radiation circular dichroism (SRCD) analysis on natural and recombinant gliadins.
  • SRCD Synchrotron radiation circular dichroism
  • nAG native (plain line) and reduced alkylated (R/A, dash line) natural ⁇ -gliadin (nAG; SEQ ID No. 1) (A); natural ⁇ - gliadin (nGG; SEQ ID No. 2) (B).
  • Figure 4 Graph illustrating the comparison of IgE binding to the full-length gliadins and to their N-terminal (Nt) or C-terminal (Ct) domains measured by ELISA. Means and medians per sample are indicated in Table 3. Statistical differences between medians of specified groups using Friedman and Dunn's multiple comparison post -test are indicated.
  • Figure 5 Graph illustrating the triggering potential of natural and recombinant a-gliadins and Nt-domain (SEQ ID No. 5) or Ct-domain (SEQ ID No. 7) tested in an Rat basophil leukaemia cell degranulation assay with a pool of 2 sera. Duplicate measurements were performed and means are represented on the graph. Abbreviations are identical to those in Figures 1 and 2.
  • Closed squares are for natural a-gliadin; closed circles are for recombinant a-gliadin; open squares are for reduced alkylated natural a-gliadin; open circles are for reduced alkylated recombinant a-gliadin; open triangles are for recombinant C-terminal domain of a-gliadin; open diamonds are for recombinant N-terminal domain of a-gliadin.
  • polypeptides comprising a N-terminal domain of an ⁇ -gliadin or a ⁇ -gliadin, or a fragment thereof may be for use as a medicament, and more precisely as antigens for desensitization of individuals affected with an allergy to gluten.
  • a polypeptide comprising the N-terminal domain of an ⁇ -gliadin is able to elicit IgE- binding, without however eliciting efficient basophils degranulation, which is normally occurring during the course of an allergic response in gluten allergy.
  • both a-gliadins and ⁇ -gliadins are proteins organized as a two-domain structure.
  • the N-terminal (Nt-) domain mainly comprises repeating motifs that are rich in glutamine and proline residues, whereas the C-terminal (Ct-) domain includes a cysteine skeleton.
  • the expression "N-terminal domain of an a-gliadin or a ⁇ -gliadin” encompasses the region of amino acids residues belonging to the N-terminal domain of an ⁇ -gliadin or a ⁇ -gliadin and may comprise at most one cysteine residue.
  • the "N-terminal domain of an ⁇ -gliadin or a ⁇ -gliadin” consists of the peptide region preceding the 1 st cysteine residue, or alternatively the peptide region including at most the 1 st cysteine residue, among the numerous cysteine residues found in the linear sequence of a full length ⁇ -gliadin or ⁇ -gliadin.
  • the "N-terminal domain of an ⁇ -gliadin or a ⁇ -gliadin” consists of the peptide region starting from the first amino acid residue at the N -terminus position, including at most the 1 st cysteine residue of the linear amino acid residues chain, and further including at most the 7 amino acid residues consecutive to the said 1 st cysteine residue.
  • fragment encompasses any polypeptide having at least 4 consecutive amino acid residues of a full length N- terminal domain of an ⁇ -gliadin or a ⁇ -gliadin.
  • the term "medicament” is intended to mean a product comprising a pharmacologically active ingredient intended to be administered to a human or animal body in order to attenuate or to cure symptoms associated with a disease.
  • Polypeptide comprised in an immunogenic composition
  • polypeptide comprising the N-terminal domain of an ⁇ -gliadin or a ⁇ - gliadin, or a fragment thereof may originate from any known plant species having been described for possessing such proteins.
  • the invention relates to polypeptides comprising the N-terminal domain of an ⁇ -gliadin or a ⁇ -gliadin, or fragments thereof originating mainly from wheat, spelt and kamut.
  • a-gliadins and ⁇ -gliadins present an important polymorphism, within one single species and among several species (Dupont et al.; Proteome Sci. 2011, 9, 10; Metakovsky et al; J. Genet. Breed 1991 , 45, 325-344). It is generally admitted in the art that the percentage of identity between two molecules of a- gliadins or two molecules of ⁇ -gliadins is about 70%. This average percentage of minimal identity is to take into consideration to evaluate the intra-species as well as the interspecies polymorphism.
  • the comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described below.
  • the percent identity between two amino acid sequences can be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4:1 1 -17, 1988) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
  • the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (J. Mol, Biol.
  • a polypeptide having at least 70% amino acid identity with a reference polypeptide sequence encompasses polypeptides having at least 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% and 100% identity with the said reference polypeptide.
  • a polypeptide comprising the N-terminal domain of an a-gliadin or a ⁇ -gliadin, or a fragment thereof may be for use as an antigenic compound.
  • the expression "antigenic compound” is intended to mean a compound able to elicit an immunologic response, notably through the production of antibodies, when administered in a human or animal body in an appropriate form (e.g. as an immune-conjugate in a composition further comprising an immuno-adjuvant substance).
  • said production of antibodies accounts for the specific production of IgGs.
  • a polypeptide comprising the N-terminal domain of an a-gliadin or a ⁇ -gliadin, or a fragment thereof may be for use as an agent for desensitization of an individual with an IgE-dependent gluten allergy.
  • the term "desensitization of an individual with an IgE-dependent gluten allergy” is intended to mean a process during which an individual with an IgE-dependent gluten allergy is stimulated with one single dose or alternatively with gradually increasing doses of the substances to which a person is allergic in order to modify or stop the allergic response.
  • said IgE-dependent gluten allergy is select in the group of durum wheat allergy, bread wheat allergy, spelt allergy, kamut allergy.
  • wheat (bran, durum, germ, gluten, grass, malt, sprouts, starch), spelt and/or kamut may be found in food products such as bread crumbs, bulgur, cereal extract, club wheat, couscous, cracker meal, einkorn, emmer, farina, flour (all purpose, bread, cake, durum, enriched, graham, high gluten, high protein, instant, pastry, self-rising, soft wheat, steel ground, stone ground, whole wheat), hydrolyzed wheat protein, matzoh (also known as matzo, matzah, or matza), pasta, instantan, semolina, sprouted wheat, triticale, vital wheat gluten, wheat bran hydrolysate, wheat germ oil, wheat grass, wheat protein isolate, whole wheat berries.
  • Traces of wheat, spelt and/or kamut may also be found in food products such as ale, baking mixes, baked products, batter-fried foods, beer, breaded foods, breakfast cereals, candy, crackers, glucose syrup, hot dogs, ice cream, imitation crabmeat, marinara sauce, play dough, potato chips, processed meats, rice cakes, salad dressings, sauces, soups, soy sauce, starch (gelatinized starch, modified starch, modified food starch, vegetable starch), surimi and turkey patties.
  • food products such as ale, baking mixes, baked products, batter-fried foods, beer, breaded foods, breakfast cereals, candy, crackers, glucose syrup, hot dogs, ice cream, imitation crabmeat, marinara sauce, play dough, potato chips, processed meats, rice cakes, salad dressings, sauces, soups, soy sauce, starch (gelatinized starch, modified starch, modified food starch, vegetable starch), surimi and turkey patties.
  • said IgE-dependent gluten allergy is a cross-allergy between a-gliadin allergy and ⁇ -gliadin allergy.
  • said polypeptide is a recombinant polypeptide.
  • Any routinely method to obtain a recombinant polypeptide according to the invention may be employed by a skilled in the art.
  • a skilled in the art may adapt suitable protocols from the available genetic engineering techniques to provide such recombinant polypeptides.
  • the techniques allowing for DNA recombination, DNA cloning, DNA incorporation into a suitable host, selection of the appropriate promoters are within the skills of an artisan in the art, as well as the techniques allowing for polypeptide purification (see e.g. Green and Sambrook; Molecular Cloning, A Laboratory Manual; 4th Edition, 2012; Cold Spring Harbor Laboratory Press).
  • said polypeptide may be obtained by chemical synthesis, accordingly to methods known in the state in the art.
  • polypeptides according to the invention may be synthesized by the so lid -phase synthesis method initially developed by Merrifield (Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. J. Am. Chem. Soc. 85 (14): 2149-2154), by the liquid-phase synthesis method (Bayer and Mutter. Nature 237, 512 - 513 (30 June 1972)).
  • the polypeptide according to the invention is a reduced polypeptide.
  • polypeptide according to the invention is an alkylated polypeptide.
  • the polypeptide according to the invention is a reduced and/or alkylated polypeptide.
  • the polypeptide according to the invention is a reduced and alkylated polypeptide.
  • reduced and/or alkylated polypeptides of the N-terminal domain of a-gliadin or a ⁇ -gliadin may be of use as an epitope capable of binding to IgEs, without, however, promoting degranulation of basophiles.
  • LTP1 lipid transfer protein
  • Treatment of the polypeptide in the presence of one or more reducing agents such as tris(2-carboxyethyl) phosphine (TCEP) or dithiothreitol (DTT), optionally in the presence of urea, ammonium bicarbonate or any mixture thereof, in the appropriate conditions of temperature and time may be applicable.
  • This step allows for disulphide reduction.
  • the free sulfhydryl groups on the cysteine residues may subsequently be alkylated with reagents such as iodoacetamide (IAA) or iodoacetic acid to irreversibly prevent the free sulfhydryls from reforming disulphide bonds.
  • a recombinant polypeptide according to the invention is reduced with DTT and alkylated with iodoacetamide during the purification steps.
  • said polypeptide has a length ranging from 10 to 200 amino acid residues.
  • the polypeptide according to the invention comprises the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an a- gliadin.
  • the "N-terminal domain of an a-gliadin" does not comprise any cysteine residue.
  • the "N-terminal domain of an a-gliadin” consists of the peptide region starting from the first amino acid residue at the N -terminus position, including at most the 1 st cysteine residue of the linear amino acid residues chain, and with the proviso that the N-terminal domain further includes no more than 7 amino acid residues consecutive to the said 1 st cysteine residue.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an a-gliadin comprises a plurality of peptides, said peptides being recognized by IgEs from gluten allergic individuals, and said peptides being selected in a group of peptides having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 9 to SEQ ID No. 33 and by the sequences SEQ ID No. 65 to SEQ ID No. 77.
  • said peptides from a plurality of peptides are linearly adjacent to one another, or spatially distant from one another and therefore separated by a stretch of amino acids.
  • a plurality of peptides is intended to encompass at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8 peptides.
  • the expression "at least 2 peptides” encompasses 2, 3, 4, 5, 6, 7, 8, 9, 10 or more peptides; the expression “at least 3 peptides” encompasses 3, 4, 5, 6, 7, 8, 9, 10 or more peptides; the expression “at least 4 peptides” encompasses 4, 5, 6, 7, 8, 9, 10 or more peptides; the expression “at least 5 peptides” encompasses 5, 6, 7, 8, 9, 10 or more peptides; the expression “at least 6 peptides” encompasses 6, 7, 8, 9, 10 or more peptides; the expression “at least 7 peptides” encompasses 7, 8, 9, 10 or more peptides; the expression “at least 8 peptides” encompasses 8, 9, 10 or more peptides.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an ⁇ -gliadin comprises a plurality of peptides, said peptides being recognized by IgEs from gluten allergic individuals, and said peptides being selected in a group of peptides represented by the sequences SEQ ID No . 9 to SEQ ID No. 33 and by the sequences SEQ ID No. 65 to SEQ ID No. 77.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an ⁇ -gliadin comprises a plurality of peptides, said peptides being recognized by IgEs from gluten allergic individuals, and said peptides being selected in a group of peptides having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 9, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 14, SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24, SEQ ID No. 27, SEQ ID No. 29, SEQ ID No. 31 and SEQ ID No. 33.
  • a polypeptide comprising the N-terminal domain of an -gliadin, or a fragment of the N-terminal domain of an -gliadin comprises a plurality of peptides, said peptides being recognized by IgEs from gluten allergic individuals, and said peptides being selected in a group of peptides represented by the sequences SEQ ID No. 9, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 14, SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24, SEQ ID No. 27, SEQ ID No. 29, SEQ ID No. 31 and SEQ ID No. 33.
  • a polypeptide comprising the N- terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an a-gliadin comprises a plurality of peptides, said peptides being recognized by IgEs from gluten allergic individuals, and said peptides being selected in a group of peptides having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 9, SEQ ID No. 12, SEQ ID No. 14 and SEQ ID No. 17.
  • a polypeptide comprising the N- terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an a-gliadin comprises a plurality of peptides, said peptides being recognized by IgEs from gluten allergic individuals, and said peptides being selected in a group of peptides represented by the sequences SEQ ID No. 9, SEQ ID No. 12, SEQ ID No. 14 and SEQ ID No. 17.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 9, SEQ ID No. 10 and SEQ ID No. 11.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and represented by the sequences SEQ ID No. 9, SEQ ID No. 10 and SEQ ID No. 11.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 14 and SEQ ID No. 16.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an a-gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and represented by the sequences SEQ ID No. 14 and SEQ ID No. 16.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 13 and SEQ ID No. 15.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and represented by the sequences SEQ ID No. 13 and SEQ ID No. 15.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 9, SEQ ID No. 11, SEQ ID No. 18, SEQ ID No. 19 and SEQ ID No. 20.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and represented by the sequences SEQ ID No. 9, SEQ ID No. 11, SEQ ID No. 18, SEQ ID No. 19 and SEQ ID No. 20.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24 and SEQ ID No. 27.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an a-gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and represented by the sequences SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24 and SEQ ID No. 27.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 21, SEQ ID No. 25 and SEQ ID No. 26.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and represented by the sequences SEQ ID No. 21, SEQ ID No. 25 and SEQ ID No. 26.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 29 and SEQ ID No. 30.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and represented by the sequences SEQ ID No. 29 and SEQ ID No. 30.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 28 and SEQ ID No. 30.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and represented by the sequences SEQ ID No. 28 and SEQ ID No. 30.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an a-gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 9, SEQ ID No. 31 and SEQ ID No. 33.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and represented by the sequences SEQ ID No. 9, SEQ ID No. 31 and SEQ ID No. 33.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 9, SEQ ID No. 31 and SEQ ID No. 32.
  • a polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and represented by the sequences SEQ ID No. 9, SEQ ID No. 31 and SEQ ID No. 32.
  • the polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an ⁇ -gliadin has at least 70% amino acid identity with the polypeptide of SEQ ID No. 5.
  • the polypeptide comprising the N-terminal domain of an a-gliadin, or a fragment of the N-terminal domain of an ⁇ -gliadin consists of the polypeptide of SEQ ID No. 5.
  • the polypeptide according to the invention comprises the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ - gliadin.
  • the "N-terminal domain of a ⁇ -gliadin” encompasses the region of amino acids residues belonging to the N-terminal domain of a ⁇ -gliadin preceding and not including the 1 st cysteine residue. In other words, the "N-terminal domain of a ⁇ -gliadin” may not comprise any cysteine residue.
  • the "N-terminal domain of a ⁇ -gliadin" consists of the peptide region comprising the 1 st cysteine residue, with the proviso that the N-terminal domain further includes no more than 7.
  • a polypeptide comprising the N-terminal domain of a ⁇ - gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises a plurality of peptides, said peptides being recognized by IgEs from gluten allergic individuals, and said peptides being selected in a group of peptides having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 34 to SEQ ID No. 64 and by the sequences SEQ ID No. 78 to SEQ ID No. 83.
  • a polypeptide comprising the N-terminal domain of a ⁇ - gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises a plurality of peptides, said peptides being recognized by IgEs from gluten allergic individuals, and said peptides being selected in a group of peptides represented by the sequences SEQ ID No. 34 to SEQ ID No. 64 and by the sequences SEQ ID No. 78 to SEQ ID No. 83.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises a plurality of peptides, said peptides being recognized by IgEs from gluten allergic individuals, and said peptides being selected in a group of peptides having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 34, SEQ ID No. 35, SEQ ID No. 37, SEQ ID No. 38, SEQ ID No. 39, SEQ ID No. 40, SEQ ID No. 41, SEQ ID No. 42, SEQ ID No. 43, SEQ ID No. 45, SEQ ID No. 47, SEQ ID No.
  • SEQ ID No. 50 SEQ ID No. 51, SEQ ID No. 52, SEQ ID No. 53, SEQ ID No. 54, SEQ ID No. 55, SEQ ID No. 56, SEQ ID No. 57, SEQ ID No. 59, SEQ ID No. 60, SEQ ID No. 62, SEQ ID No. 63 and SEQ ID No. 64.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises a plurality of peptides, said peptides being recognized by IgEs from gluten allergic individuals, said peptides being selected in a group of peptides represented by the sequences SEQ ID No. 34, SEQ ID No. 35, SEQ ID No. 37, SEQ ID No. 38, SEQ ID No. 39, SEQ ID No. 40, SEQ ID No. 41, SEQ ID No. 42, SEQ ID No. 43, SEQ ID No. 45, SEQ ID No. 47, SEQ ID No. 49, SEQ ID No. 50, SEQ ID No.
  • SEQ ID No. 52 SEQ ID No. 53, SEQ ID No. 54, SEQ ID No. 55, SEQ ID No. 56, SEQ ID No. 57, SEQ ID No. 59, SEQ ID No. 60, SEQ ID No. 62, SEQ ID No. 63 and SEQ ID No. 64.
  • the polypeptide comprising the N -terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises a plurality of peptides, said peptides being recognized by IgEs from gluten allergic individuals, said peptides being selected in a group of peptides having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 35, SEQ ID No. 43, SEQ ID No. 50, SEQ ID No. 57, SEQ ID No. 60 and SEQ ID No. 64.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises a plurality of peptides, said peptides being recognized by IgEs from gluten allergic individuals, said peptides being selected in a group of peptides represented by the sequences SEQ ID No. 35, SEQ ID No. 43, SEQ ID No. 50, SEQ ID No. 57, SEQ ID No. 60 and SEQ ID No. 64.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 34, SEQ ID No. 37, SEQ ID No. 38, SEQ ID No. 39, SEQ ID No. 40 and SEQ ID No. 41.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and represented by the sequences SEQ ID No. 34, SEQ ID No. 37, SEQ ID No. 38, SEQ ID No. 39, SEQ ID No. 40 and SEQ ID No. 41.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 34, SEQ ID No. 36 and SEQ ID No. 41.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and represented by the sequences SEQ ID No. 34, SEQ ID No. 36 and SEQ ID No. 41.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 42 and SEQ ID No. 45.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and represented by the sequences SEQ ID No. 42 and SEQ ID No. 45.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 42 and SEQ ID No. 44.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and represented by the sequences SEQ ID No. 42 and SEQ ID No. 44.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 47, SEQ ID No. 49, SEQ ID No. 51, SEQ ID No. 52, SEQ ID No. 53, SEQ ID No. 54 and SEQ ID No. 55.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and represented by the sequences SEQ ID No. 47, SEQ ID No. 49, SEQ ID No. 51 , SEQ ID No. 52, SEQ ID No. 53, SEQ ID No. 54 and SEQ ID No. 55.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 46 and SEQ ID No. 48.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and represented by the sequences SEQ ID No. 46 and SEQ ID No. 48.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 56 and SEQ ID No. 57.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and represented by the sequences SEQ ID No. 56 and SEQ ID No. 57.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 56 and SEQ ID No. 58.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and represented by the sequences SEQ ID No. 56 and SEQ ID No. 58.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 62, SEQ ID No. 63 and SEQ ID No. 64.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises the peptides recognized by IgEs from gluten allergic individuals and represented by the sequences SEQ ID No. 62, SEQ ID No. 63 and SEQ ID No. 64.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises the peptide recognized by IgEs from gluten allergic individuals and having at least 70% amino acid identity with peptides represented by the sequence SEQ ID No. 61.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin comprises the peptide recognized by IgEs from gluten allergic individuals and represented by the sequence SEQ ID No. 61.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin has at least 70% amino acid identity with the polypeptide of SEQ ID No. 6.
  • the polypeptide comprising the N-terminal domain of a ⁇ -gliadin, or a fragment of the N-terminal domain of a ⁇ -gliadin consists of the polypeptide of SEQ ID No. 6.
  • a polypeptide according to the invention is a hetero- polypeptide comprising, in a one single amino acids sequence,
  • a hetero-polypeptide comprising, in a one single amino acids sequence
  • ⁇ -gliadin allergy may be for use as an agent for desensitization of an individual with an IgE -dependent gluten allergy, resulting from a cross-allergy between ⁇ -gliadin allergy and ⁇ -gliadin allergy.
  • said hetero-polypeptide has a length ranging from 10 to 400 amino acid residues.
  • "From 10 to 400 amino acid residues” encompasses hetero -polypeptides having 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105,
  • hetero -polypeptide according to the invention may comprise:
  • peptide recognized by IgEs from gluten allergic individuals, said peptide being selected in a group of peptides having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 9 to SEQ ID No. 33;
  • peptide recognized by IgEs from gluten allergic individuals, said peptide being selected in a group of peptides having at least 70% amino acid identity with peptides represented by the sequences SEQ ID No. 34 to SEQ ID No. 64.
  • Another aspect of the invention relates to an immunogenic composition
  • an immunogenic composition comprising:
  • the expression “immunogenic composition” encompasses a composition able to elicit an immunogenic response after being in contact with a living animal or human body.
  • immunogenic response a skilled in the art understands a response feature by the production of IgG antibodies, in a human body.
  • the expression “a mixture of polypeptides” encompasses at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10 polypeptides according to the invention.
  • said mixture may comprise polypeptides comprising the N-terminal domain of a-gliadins or ⁇ -gliadins originating from the same plant species, or a fragment thereof. In some embodiments, said mixture may comprise polypeptides comprising the N-terminal domain of a-gliadins or ⁇ -gliadins originating from different plant species, or a fragment thereof.
  • said mixture may comprise polypeptides comprising the N-terminal domain of a-gliadin(s) and y-gliadin(s) originating from the same plant species, or a fragment thereof. In some embodiments, said mixture may comprise polypeptides comprising the N-terminal domain of a-gliadin(s) and y-gliadin(s) originating from different plant species, or a fragment thereof.
  • Physiologically acceptable adjuvants encompass, but are not limited to, StimulonTM, QS-21 (Aquila Biopharmaceuticals, Inc., Framingham, Mass.); MPLTM (3-0- deacylated monophosphoryl lipid A; Corixa, Hamilton, Mont.), 529 (an amino alkyl glucosamine phosphate compound, Corixa, Hamilton, Mont.), IL-12 (Genetics Institute, Cambridge, Mass.); GM-CSF (Immunex Corp., Seattle, Wash.); N-acetyl-muramyl-L- theronyl-D-isoglutamine (thr-MDP); N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP); N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L- alanine-2-( -2'-dipalmitoy
  • physiologically acceptable adjuvants encompass non-toxic derivatives of cholera toxin, including its A subunit, and/or conjugates or genetically engineered fusions of the N. meningitidis polypeptide with cholera toxin or its B subunit ("CTB”), procholeragenoid, fungal polysaccharides, including schizophyllan, muramyl dipeptide, muramyl dipeptide (“MDP”) derivatives, phorbol esters, the heat labile toxin of E. coli, block polymers or saponins.
  • CTB N. meningitidis polypeptide with cholera toxin or its B subunit
  • procholeragenoid procholeragenoid
  • fungal polysaccharides including schizophyllan, muramyl dipeptide, muramyl dipeptide (“MDP”) derivatives
  • phorbol esters the heat labile toxin of E. coli, block polymers or saponins.
  • composition according to the invention claim 13, wherein the said polypeptide(s) is(are) covalently linked to a carrier molecule.
  • a polypeptide according to the invention is advantageously covalently linked to a carrier molecule when said polypeptide has a length comprised between 4 and 29 amino acids.
  • the types of carrier molecules routinely used for generating an immunogenic product comprising a polypeptide according to the invention linked to a carrier molecule are belonging to the common knowledge of a skilled in the art.
  • the carrier molecule is intended to provide cytokine help (or T-cell help) in order to enhance the immune response against the allergenic polypeptide according to the invention.
  • the carrier molecule to which the peptide is optionally bound can be selected from a wide variety of known carriers.
  • carrier molecules for immunotherapy purposes encompass proteins such as human or bovine serum albumin and keyhole limpet haemocyanin (KLH) and fatty acids.
  • KLH keyhole limpet haemocyanin
  • Other embodiments of carrier molecules to which an antigenic polypeptide according to the invention may be covalently linked include bacterial toxins or toxoids, such as diphtheria, cholera, E. coli heat labile or tetanus toxoids, the N.
  • the immunogenic composition according to the invention is in the form of a live attenuated vaccine comprising a recombinant live organism, of viral or bacterial origin, the said live organism expressing one or more polypeptide(s) as defined above.
  • live attenuated vaccine encompasses vaccine compositions containing a version of a living microbe that has been modified so that it cannot elicit the corresponding disease when administered in a living animal or human body.
  • Live attenuated vaccine may elicit strong cellular and antibody responses and often confer lifelong immunity with only one or two doses.
  • a recombinant live organism of viral origin may be selected in a group comprising the vaccine virus, the poliomyelitis virus, adenoviruses and retroviruses.
  • a recombinant live organism of bacterial origin may be selected in a group comprising Salmonella typhi strains, Mycobacterium bovis strains, Listeria monocytogenes strains, Bordetella pertussis strains, Shigella sp. strains, Streptococcus gordonii strains, Lactococcus lactis strains, Lactobacillus sp. strains, Staphylococcus xylosus strains and Staphylococcus carnosus strains.
  • said recombinant live organism is expressing one or more polypeptide(s) as defined above.
  • recombinant DNA encoding said polypeptide(s) are incorporated in said virus or said bacteria, directly in the genome of said live organism.
  • bacterial live attenuated organism may include a plasmid or cosmid vector comprising a DNA encoding said polypeptide(s) to be produced.
  • the immunogenic composition according to the invention is for use as a medicament.
  • the immunogenic composition according to the invention is for use as an antigenic compound.
  • the immunogenic composition according to the invention is for use as an agent for desensitization of an IgE -dependent gluten allergy.
  • Immunogenic compositions of the invention preferably include at least one pharmaceutically acceptable excipient.
  • Suitable pharmaceutically acceptable excipients include, but are not limited to, any and all conventional solvents, dispersion media, fillers, solid carriers, aqueous solutions, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like.
  • Suitable pharmaceutically acceptable excipients include, for example, water, saline buffer, phosphate buffered saline buffer, dextrose, glycerol, ethanol and the like, as well as combinations thereof.
  • compositions of the present invention may further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives, which enhance the shelf life or effectiveness of the immunogenic composition.
  • auxiliary substances such as wetting or emulsifying agents, preservatives, which enhance the shelf life or effectiveness of the immunogenic composition.
  • the preparation and use of pharmaceutically acceptable excipients is well known in the art. Except insofar as any conventional media or agent is incompatible with the polypeptide according to the invention, use thereof in the immunogenic compositions of the present invention is contemplated.
  • Such immunogenic compositions can be administered parenterally, e.g., by injection, either subcutaneously or intramuscularly, as well as orally or intranasally.
  • Other modes of administration employ oral formulations, pulmonary formulations, suppositories, and transdermal applications, for example, without limitation.
  • Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like, without limitation.
  • the present invention also relates to a method for desensitization of an individual with an IgE-dependent gluten allergy comprising a step of administering to said individual an immunogenic composition comprising a polypeptide comprising a N- terminal domain of an a-gliadin or a ⁇ -gliadin, or a fragment thereof, optionally linked to a carrier molecule.
  • an immunogenic composition according to the invention comprises a polypeptide comprising a N-terminal domain of an a-gliadin or a ⁇ - gliadin, or a fragment thereof, in an amount which is suitable for the administration of from 1 ⁇ g to 1000 mg, which encompasses from 10 ⁇ g to 1 mg, of said polypeptide to an individual in need thereof, for therapeutic purposes.
  • the amount of said polypeptide to be administered to an individual in need thereof depends of the age, the gender, the weight and the further medical condition of said individual and may be of at least 200 ⁇ g, 500 ⁇ g, or lmg, preferably at most 1000 mg.
  • the amount of said polypeptide specified above also applies when the immunogenic composition comprises said polypeptide in a conjugated form with a carrier molecule.
  • an immunogenic composition is administered at least twice to an individual in need thereof.
  • the second step of administration of an immunogenic composition according to the invention is performed in a time period of from 2 weeks to 6 months after the first administration step.
  • an immunogenic composition is administered at least three times to an individual in need thereof.
  • the second step of administration of the said immunogenic composition according to the invention is performed in a time period of from 2 weeks to 6 months after the first administration step.
  • the third step of administration of the said immunogenic composition is performed in a time period of from more than 6 months to about one year after the first administration step.
  • the said immunogenic composition is then again administered to a desensitized individual, for example every 5-year time period or every 10-year time period.
  • the present example aims to characterize the structural features linked to allergenicity of proteins belonging to the prolamin superfamily by focusing on two members: a- and ⁇ -gliadins.
  • Different forms (natural/recombinant; native/reduced - alkylated) and fragments (Nt- and Ct-) of a- and ⁇ -gliadins were produced to evaluate the contribution of their structural domains and disulphide bonds to IgE binding.
  • Their secondary structure was determined using synchrotron radiation circular dichroism (SRCD); sera from patients with food allergies to wheat (FAW) or baker's asthma (BA) were used to analyse IgE binding by ELISA and Pepscan; and biological activity was measured by monitoring rat basophil elicitation.
  • SRCD synchrotron radiation circular dichroism
  • FAW food allergies to wheat
  • BA baker's asthma
  • rAG SEQ ID No. 3
  • rNt-AG SEQ ID No. 5
  • rAG SEQ ID No. 3
  • rGG ⁇ -gliadin
  • Nt- and Ct- moieties were cloned by PCR.
  • the PCR was run directly using cDNA as template.
  • the DNA Polymerase used was AccuPrimeTM Pfx (Life Technologies). Fragments were cloned with restriction enzymes into a pET28b (Novagen) plasmid in frame with a sequence encoding the hexa-histidine Tag (His-Tag).
  • the sequences of the specific primers used in the cloning procedure of rAG (SEQ ID No. 3) and rNt-AG (SEQ ID No. 5) are described in Mameri et al. (see above).
  • Nested PCR technique is used, the 1 st PCR is performed with primers 1 and 2; a 2 n PCR is subsequently performed using the PCR product from the 1 PCR, with primers 1 and 3.
  • nAG SEQ ID No. 1
  • nGG SEQ ID No. 2
  • the ⁇ -gliadin corresponded to the ⁇ 46 fraction described in (Egorov et al; Biochem; 1998, 63, 1061-1067).
  • natural proteins were used after reduction/alkylation.
  • nAG (SEQ ID No. 1; 3 mg/ml) was hydrolysed at 37°C for 6 h using porcine trypsin (Sigma T8253) and Chymotrypsin (Sigma C 4879) in 25 mM NH 4 HCO 3 at an enzyme/substrate ratio of 1/100 w/w.
  • the resulting hydro lysate was reduced by mixing with 10 mM DTT and 10% acetonitrile at 45°C for 1 h in the dark with gentle stirring. After cooling the sample to room temperature, 0.5 M iodoacetamide was added and the sample was incubated for 30 min in the dark.
  • the peptides were diluted ten times in water; subsequently, 50 ⁇ of the solution was eluted on C 18 resin pipet tips (ZipTip, Millipore Corp, Billerica, MA), cleaned and finally extracted from the Zip Tip with a 30 ⁇ of 1 : 1 acetonitrile/water containing 0.05% formic acid and 50% acetonitrile. The acetonitrile was then evaporated on speed vac and the sample was stored for mass spectrometry analysis.
  • Nanoscale capillary liquid chromatography-tandem mass spectrometry (LC- MS/MS) analyses were performed using an Ultimate U3000 RSLC system (Dionex) coupled with an LTQ-Orbitrap VELOS mass spectrometer (Thermo Fisher). Chromatographic separation and mass data acquisition were performed as described in Lupi et al. (J. Cereal Sc.; 2014, 60, 179-186). Protein identification was performed using the Mascot database search engine and the UniProt databank, which was restricted to Poaceae sequences (release 2015 01). Mass tolerance for peptide precursors was set at 5 ppm, with the fragment mass tolerance set at 0.5 Da. Enzyme specificity was set to trypsin and chymotrypsin with a maximum of 1 mis-cleavage.
  • Sensitization to wheat proteins was assessed in patients using skin prick tests (SPT) to wheat flour (Moulins Soufflet), gluten (ALK-Abello) and to natural gliadins and/or using specific-IgE assays to wheat flour or gluten (Phadia ImmunoCAP).
  • SPT skin prick tests
  • a wheat allergy was confirmed by a positive challenge or evident effect of wheat avoidance.
  • the double-blind placebo-controlled food challenge and the inhalation challenge with wheat flour are described in Bensefa et al. (Allergy, 2004, 59, 833-838) and Denery-Papini et al. (Clin. Exp. Allergy, 2011, 41, 1478- 1492), respectively.
  • IgE concentrations toward the different forms of AG and GG were determined by F-ELISA as described in Mameri et al. (Molecul. Nutr. Food Res., 2012, 56, 1847-1883) using alkaline-phosphatase-conjugated goat anti-human IgE and 4-MUP as a substrate (Sigma A3525 and A3168, respectively, Saint-Quentin Fallavier, France). Proteins solubilized in PBS were coated at 5 mg/1 in carbonate buffer on white 384-well plates (NUNC 460372, Fischer Scientific).
  • Rat basophil leukaemia (RBL SX38) cell degranulation was expressed as the percentage of ⁇ -hexosaminidase release with a positive threshold set at 11% as described in Mameri et al. (Molecul. Nutr. Food Res. 2012, 56, 1874-1883). Gliadin samples were tested at 2, 20, 200 and 2000 ng/ml with a pool of 2 sera (899+907) diluted 1/10.
  • rAG SEQ ID No. 3
  • nAG SEQ ID No. 1
  • rGG SEQ ID No. 4
  • the recombinant ⁇ -gliadin was recorded under UniProt ID Q94G94.
  • the purified natural ⁇ -gliadin corresponded to a y46-gliadin type according to its electrophoretic mobility in Acid-PAGE and was previously described as protein ID P08453.
  • the rGG (SEQ ID No. 4) and nGG SEQ ID No. 2) sequences displayed 72 % identity. Their mobility in SDS-PAGE was approximately 40 kDa.
  • the Nt- and Ct- recombinant domains each constitute approximately one half of a gliadin protein and migrated approximately 15-22 kDa.
  • the mobility of the rNt-GG fragment (133 residues; SEQ ID No. 6) was faster than that of the rGG-Ct fragment (136 residues; SEQ ID No. 8).
  • the molecular weights of the prolamins are often overestimated by SDS-PAGE, which has been attributed to the high content of proline in their Nt- repetitive domains.
  • nAG SEQ ID No. 1
  • nAG SEQ ID No. 1
  • rAG SEQ ID No. 3
  • its domains displayed similar dichroic signals (Figure 2C) corresponding to a higher level of a-helix (52-58 %) and a lower level of turn structures (11%) compared with nAG (SEQ ID No. 1).
  • nGG The secondary structure contents of nGG (SEQ ID No. 2) were approximately 25% a-helix and 16%) ⁇ -strand and turns, and the reduction/alkylation of nGG (SEQ ID No. 2) did not change the CD spectrum ( Figure 2B).
  • rGG The recombinant rGG (SEQ ID No. 4) contained slightly more a-helix (37%) and fewer strands (11%) than did nGG (SEQ ID No. 2). Unlike rAG (SEQ ID No. 3), full- length rGG (SEQ ID No. 4) and its Nt-domain (SEQ ID No. 6) and Ct-domain (SEQ ID No. 8) displayed different spectra ( Figure 2D). rGG-Ct domain (SEQ ID No. 8) is notably folded in a-helices (67%). The CD spectrum of the repetitive rNt-GG domain (SEQ ID No. 6) showed an unusual negative peak at 210 nm, which is characteristic of turn structures.
  • Table 2 below indicates the sera's characteristics of patients allergic to wheat
  • the mean specific IgE concentration was twice as high for the rNt-AG (SEQ ID No. 5) as it was for rAG-Ct (SEQ ID No. 7) (39 and 20 ng/mL, respectively); IgE from 43% of sera did not bind the Ct-domain, whereas it did bind the Nt-domain.
  • the sum of the mean specific IgE concentrations for the two domains was equivalent to the mean concentration for the full-length recombinant gliadin after reduction alkylation (57 ng/mL).
  • the rGG-Ct domain (SEQ ID No. 8) was rarely bound by specific IgE (only 25% of the sera). Conversely, all sera displayed IgE binding to the rNt-GG (SEQ ID No. 6).
  • the mean concentrations of specific IgE for rNt-GG and R/A rGG binding were equivalent (36 and 32 ng/mL).
  • Table 6 IgE reactivity of sera from wheat allergic patients toward synthetic peptides screened by Pepscan analysis.
  • the five sera tested on the ⁇ -gliadin sequence displayed IgE binding to 7 to 38 peptides located in the Nt-domain (see Table 7).
  • the numerous peptides in the Nt-domain corresponding to the consensus sequences PQQPFPQQPQ, LSQQPQQTFP (SEQ ID No. 35), QPQQSFPQ or QPQQTFPQ were found with all sera, reflecting a higher homogeneity of repetition in ⁇ -gliadin than in a-gliadin.
  • Table 7 IgE reactivity of sera from wheat allergic patients toward synthetic peptides screened by Pepscan analysis.
  • Nt-domain of GG (Uniprot accession number P08453) are indicated together with stretches of sequences in which spots are detected with low (normal) and high (bold) intensity. Peptides detected with the highest intensity by serum are underlined.
  • Table 8 indicates the different peptides identified by PEPSCAN analysis in selected serum for the Nt-domain of a-gliadin (SEQ ID No. 9 to SEQ ID No. 33) and the Nt-domain of ⁇ -gliadin (SEQ ID No. 34 to SEQ ID No. 64).
  • nAG SEQ ID No. 1
  • rAG SEQ ID No. 3
  • R/A nAG SEQ ID No. 1
  • 150 ng/mL the gliadin domains
  • 70 ng/mL for rNt-AG SEQ ID No. 5
  • 100 ng/mL for rAG-Ct SEQ ID No. 7
  • nAG SEQ ID No. 1
  • rAG SEQ ID No. 3
  • maximum degranulation was obtained at a lower protein concentration for nAG (SEQ ID No. 1; 20 ng/mL) than for rAG (SEQ ID No. 3; 200 ng/mL).
  • Reduced/alkylated nAG (SEQ ID No. 1) or rAG (SEQ ID No. 3) induced low degranulation at similar concentration (200 ng/ml), and none of the recombinant domains were able to induce degranulation above the positive threshold.
  • a- and ⁇ -gliadins are polymorphic and have closely related sequences.
  • the recombinant gliadins rAG (SEQ ID No. 3) and rGG (SEQ ID No. 4) displayed 90 and 72% sequence identity to the isoforms present in the natural AG (SEQ ID No. 1) and GG (SEQ ID No. 2) purified fractions, respectively.
  • These recombinant proteins displayed higher contents in a-helical secondary structure (52% for rAG (SEQ ID No. 3) and 36% for rGG (SEQ ID No. 4)) compared with the natural fractions (36% for nAG (SEQ ID No. 1) and 25% for nGG (SEQ ID No. 2)).
  • the results from SRCD are in accordance with the previously published data.
  • rAG SEQ ID No. 3
  • the rNt-GG (SEQ ID No. 6) primarily contains turn structures, whereas the rGG-Ct (SEQ ID No. 8) contains a very high content of a-helix.
  • allergenicity of GG was less affected by the reduction of disulphide bridges and more pronounced towards its Nt-domain than in the case of AG.
  • VQQQQFPGQQQQFPPQQP Peptide from N-ter domain of a-gliadin (serum n° 130)
  • the high molecular weight glutenin subunit Bx7 allergen from wheat contains repetitive IgE epitopes. Allergy 2014, 69, 1316-1323.
  • Bittner, C Grassau, B., Frenzel, K., Baur, X., Identification of wheat gliadins as an allergen family related to baker's asthma. J Allergy Clin Immunol 2008, 121, 744- 749.
  • Senger S Maurano F, Mazzeo MF, Gaita M, et al., Identification of immunodominant epitopes of alpha-gliadin in HLA-DQ8 transgenic mice following oral immunization. J Immunol. 2005 Dec 15;175(12):8087-95.
  • Van Stokkum I., Spoelder, H., Bloemendal, M., Van Grondelle, R., Groen, F.,

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition immunogène comprenant un polypeptide ou un mélange de polypeptides comprenant le domaine N-terminal d'une α-gliadine ou d'une γ-gliadine, ou un fragment du domaine N-terminal d'une α-gliadine ou d'une γ-gliadine ; et au moins un adjuvant physiologiquement acceptable.
EP16733421.8A 2015-06-26 2016-06-24 Composition immunogène Withdrawn EP3313868A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21163171.8A EP3868777A1 (fr) 2015-06-26 2016-06-24 Composition immunogène

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2015306013 2015-06-26
PCT/EP2016/064697 WO2016207367A1 (fr) 2015-06-26 2016-06-24 Composition immunogène

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP21163171.8A Division EP3868777A1 (fr) 2015-06-26 2016-06-24 Composition immunogène

Publications (1)

Publication Number Publication Date
EP3313868A1 true EP3313868A1 (fr) 2018-05-02

Family

ID=61828415

Family Applications (2)

Application Number Title Priority Date Filing Date
EP21163171.8A Withdrawn EP3868777A1 (fr) 2015-06-26 2016-06-24 Composition immunogène
EP16733421.8A Withdrawn EP3313868A1 (fr) 2015-06-26 2016-06-24 Composition immunogène

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP21163171.8A Withdrawn EP3868777A1 (fr) 2015-06-26 2016-06-24 Composition immunogène

Country Status (1)

Country Link
EP (2) EP3868777A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212885D0 (en) * 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof

Also Published As

Publication number Publication date
EP3868777A1 (fr) 2021-08-25

Similar Documents

Publication Publication Date Title
Palladino et al. Peanut allergens
Verhoeckx et al. Food processing and allergenicity
Robotham et al. Ana o 3, an important cashew nut (Anacardium occidentale L.) allergen of the 2S albumin family
Costa et al. Almond allergens: molecular characterization, detection, and clinical relevance
Asturias et al. Diagnosis of Alternaria alternata sensitization with natural and recombinant Alt a 1 allergens
Ahrazem et al. Lipid transfer proteins and allergy to oranges
Hofer et al. Tackling Bet v 1 and associated food allergies with a single hybrid protein
EP1377604B1 (fr) Procedes et moyens a utiliser pour des recepteurs de cellules t restreintes au hla-dq et peptides derives de prolamine se liant a hla-dq
Monsalve et al. Allergy to mustard seeds: the importance of 2S albumins as food allergens
CN109942689B (zh) 表位
Tohgi et al. Usability of Fag e 2 ImmunoCAP in the diagnosis of buckwheat allergy
TR201812060T4 (tr) Hipoalerjen.
US9040054B2 (en) Hypoallergenic molecules
KR20200143291A (ko) 알레르기 항원 및 그 에피토프
Palomares et al. Cloning, sequencing, and recombinant production of Sin a 2, an allergenic 11S globulin from yellow mustard seeds
Glaspole et al. Clinical allergy to hazelnut and peanut: identification of T cell cross-reactive allergens
WO2018199341A1 (fr) Antigène d'allergie et épitope associé
Wopfner et al. The alpha and beta subchain of Amb a 1, the major ragweed-pollen allergen show divergent reactivity at the IgE and T-cell level
US20140037661A1 (en) Wheat Antigens and Peptides for Diagnosis of Wheat Induced Hypersensitivity
Reese et al. Food allergens
US20180193450A1 (en) Immunogenic composition
EP3868777A1 (fr) Composition immunogène
CN111051336A (zh) 变态反应的抗原及其表位
EP2794644B1 (fr) Variants hypoalergeniques de l'allergène majeur phl p 5 de phleum pratense
Jędrychowski et al. State of the art on food allergens-a review.

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180126

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LARRE, COLETTE

Inventor name: DENERY, SANDRA

Inventor name: BROSSARD, CHANTAL

Inventor name: TRANQUET, OLIVIER

Inventor name: GAUDIN, JEAN-CHARLES

Inventor name: SNEGAROFF, JACQUES

Inventor name: MAMERI, HAMZA

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190710

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210330